Skip to main content
Multiple Sclerosis Discovery Forum
User Top Menu
Who We Are
How to Cite
News & Future Directions
Essays & Opinions
Meetings & Events
Clinical Trials - Public Availability of Results
MS trials baseline
Map of MS Prevalence
Progressive MS Authors Galaxy
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Scientific Literature TreeMap
Clinical Trials in MS
Click Here to Support MSDF
You are here
Most Viewed Papers
Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis.
Multiple sclerosis from the standpoint of geographic distribution and race
Disseminated sclerosis in South Africa; its relationship to swayback disease and suggested treatment.
MRI as an outcome in multiple sclerosis clinical trials.
Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients.
Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables.
No shortcuts to outcome in MS clinical trials?
The influence of nutritional factors on the prognosis of multiple sclerosis.
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.
Lectures on the diseases of the nervous system.
Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica.
MRI in multiple sclerosis: current status and future prospects.
Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis.
One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis.
ω-3 Fatty Acid Treatment in Multiple Sclerosis (OFAMS Study): A Randomized, Double-Blind, Placebo-Controlled Trial.
Experimental models of multiple sclerosis.
LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis.
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
Treating multiple sclerosis with monoclonal antibodies: a 2010 update.
MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals.
Safety study of BIIB033 in subjects with multiple sclerosis
Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation.
A regenerative approach to the treatment of multiple sclerosis.
Histologie de la sclerose en plaques
Autoimmunity's next top models.